TSX-049 successfully completed first part of a multiple formulation study and the initiation fo the second part

TSX-049 successfully completed the first part of a multiple formulation study in canines and the initiation of the second and final part of the study in collaboration with ASKA Pharmaceutical.

Part one of the study showed TSX-049 to have the improved absorption curves and established serum testosterone levels of up to four times higher than its predecessor, TSX-011. Successful completion of the study would allow for human clinical trials to be initiated by Q2 2020 with potential U.S. Food and Drug Administration approval as soon as 2023.

Read more about the predecessor TSX-011 trial.